Physician profile
Jennifer Lauren Broad
NPI 1801039821
$6,612.76
in general payments reported to CMS, 2019-2025
29 companies · $644 in 2025
The $644 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $794 · 2021: $1,089 · 2022: $2,441 · 2023: $1,008 · 2024: $438 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,026 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,025.89 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $1,976.64 | 2021-2025 | Phexxi, Solosec, Phexx |
| Abbvie INC. | $1,261.97 | 2019-2023 | Lo Loestrin Fe, Liletta, Orilissa |
| Pfizer INC. | $586.60 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $584.17 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $358.07 | 2022-2025 | |
| Exeltis, USA INC. | $229.87 | 2019-2025 | Slynd |
| Coopersurgical, INC. | $165.31 | 2020-2022 | |
| Hologic Sales and Service, LLC | $160.16 | 2020-2023 | Aptima |
| Organon LLC | $148.66 | 2021-2025 | Nexplanon |
| Biogen, INC. | $131.41 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $120.26 | 2023 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $113.63 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Agile Therapeutics, INC. | $79.35 | 2021-2024 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $76.51 | 2019-2023 | |
| Therapeuticsmd, INC. | $67.91 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $61.57 | 2019-2020 | |
| Aspira Women'S Health INC | $58.44 | 2022-2024 | Ova1 |
| Daiichi Sankyo INC. | $52.09 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $51.25 | 2021-2022 | |
| Roche Diagnostics Corporation | $50.01 | 2020-2021 | |
| Amgen INC. | $47.63 | 2020 | |
| Vertical Pharmaceuticals, LLC | $44.17 | 2019-2020 | |
| Myovant Sciences INC. | $41.01 | 2022 | |
| Merck Sharp & Dohme LLC | $38.54 | 2020-2021 | |
| Lupin INC. | $38.18 | 2020 | |
| Forte Bio-Pharma LLC | $23.87 | 2019-2020 | |
| Shield Therapeutics INC | $16.95 | 2023 | Accrufer |
| Medicem INC. | $14.77 | 2021 | |
| Virtus Pharmaceuticals LLC | $13.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Broad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.